Biologically active cannabidiol analogs

US11344525B2 · kind B2 · utility

Assignee

• UNIVERSITY OF MISSISSIPPI · US

Inventors

• Mahmoud A. ElSohly · Oxford, US
• Soumyajit Majumdar · Oxford, US
• Waseem Gul · Oxford, US
• Mohammad Khalid Ashfaq · Oxford, US
• Kenneth Joseph Sufka · Oxford, US
• Hannah Marie Harris · Kiln, US

Key dates

• Filing date: Jun 9, 2020
• Grant date: May 31, 2022
• Expiry date: Jun 9, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.